BR112013013166A2 - tratamentos da infecção pelo vírus da hepatite c - Google Patents

tratamentos da infecção pelo vírus da hepatite c

Info

Publication number
BR112013013166A2
BR112013013166A2 BR112013013166A BR112013013166A BR112013013166A2 BR 112013013166 A2 BR112013013166 A2 BR 112013013166A2 BR 112013013166 A BR112013013166 A BR 112013013166A BR 112013013166 A BR112013013166 A BR 112013013166A BR 112013013166 A2 BR112013013166 A2 BR 112013013166A2
Authority
BR
Brazil
Prior art keywords
hepatitis
virus infection
infection treatments
treatments
virus
Prior art date
Application number
BR112013013166A
Other languages
English (en)
Inventor
Claudio Avila
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013013166A2 publication Critical patent/BR112013013166A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112013013166A 2010-11-30 2011-11-29 tratamentos da infecção pelo vírus da hepatite c BR112013013166A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41813710P 2010-11-30 2010-11-30
PCT/EP2011/071330 WO2012072655A1 (en) 2010-11-30 2011-11-29 New treatments of hepatitis c virus infection

Publications (1)

Publication Number Publication Date
BR112013013166A2 true BR112013013166A2 (pt) 2016-09-06

Family

ID=45047818

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013166A BR112013013166A2 (pt) 2010-11-30 2011-11-29 tratamentos da infecção pelo vírus da hepatite c

Country Status (11)

Country Link
US (3) US20130251678A1 (pt)
EP (1) EP2646038A1 (pt)
JP (1) JP6110791B2 (pt)
KR (1) KR20140001966A (pt)
CN (2) CN105381450A (pt)
AU (2) AU2011334984A1 (pt)
BR (1) BR112013013166A2 (pt)
CA (1) CA2818067A1 (pt)
MX (1) MX2013006052A (pt)
RU (1) RU2013129824A (pt)
WO (1) WO2012072655A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140228281A1 (en) * 2011-09-27 2014-08-14 Novartis Ag Alisporivr for treatment of hepatitis c virus infection
WO2015008223A1 (en) * 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
MX2016012799A (es) * 2014-04-02 2016-12-12 Abbvie Inc Metodos para tratar el virus de la hepatitis c.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6924270B2 (en) * 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2006038088A1 (en) * 2004-10-01 2006-04-13 Debiopharm Sa Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
JP2008525459A (ja) 2004-12-23 2008-07-17 ノバルティス アクチエンゲゼルシャフト Ｈｃｖ処置用組成物

Also Published As

Publication number Publication date
AU2011334984A1 (en) 2013-07-04
WO2012072655A1 (en) 2012-06-07
JP6110791B2 (ja) 2017-04-05
AU2016200370A1 (en) 2016-02-11
MX2013006052A (es) 2013-06-18
EP2646038A1 (en) 2013-10-09
KR20140001966A (ko) 2014-01-07
US20150273015A1 (en) 2015-10-01
US20130251678A1 (en) 2013-09-26
CN103221053A (zh) 2013-07-24
JP2013545765A (ja) 2013-12-26
CA2818067A1 (en) 2012-06-07
RU2013129824A (ru) 2015-01-10
US20170224765A1 (en) 2017-08-10
CN105381450A (zh) 2016-03-09

Similar Documents

Publication Publication Date Title
CY2018029I2 (el) Αντι-ιικη θεραπεια
CY2015012I2 (el) Αναστολεις του ιου της ηπατιτιδας c
BRPI1014084A2 (pt) inibidores do vírus da hepatite c
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
BRPI1007836A2 (pt) Inibidores do vírus c da hepatite
BRPI1008846A2 (pt) inibidores do vírus da hepatite c
SMT201600470B (it) Inibitori del virus dell'epatite c
CY2017025I1 (el) Αντιδοτα αντιπηκτικων
BRPI1010506A2 (pt) "inibidores do vírus da hepatite c"
BRPI0908240A2 (pt) inibidores do vírus da hepatite c
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
CO6862103A2 (es) Modulación de la expresión del virus de la hepatitis b (vhb)
BR112013004520A2 (pt) inibidores potentes e seletivos do virus da hepatite c
SMT201700029B (it) Inibitori del virus dell'epatite c
DK2903967T3 (da) Acylaminopyrimidinderivater til behandling af virusinfektioner og yderligere sygdomme
DK3311824T3 (da) Cd47 målrettede terapier til behandlingen af infektionssygdomme
BR112013014063A2 (pt) inibidores macrocíclicos do vírus flaviviridae
DK3124610T3 (da) Hbv-behandling
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
CO6821952A2 (es) Inihibidores del virus de la hepatitis c
DK2935313T3 (da) Vacciner mod hepatitis B-virus
ZA201205547B (en) Therapies for treating hepatitis c virus infection
SMT201600059B (it) Trattamento di infezioni da streptococco
DK2590565T3 (da) Blodprøvetagning
BRPI0923034A2 (pt) terapia de combinação para virus da hepatite c

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.